Furthermore, inhibition of ETS1 might be of therapeutic interest in the context of brain cancer or neurodegenerative diseases in which insufficient immune responses in the CNS can contribute to pathology49,50. This evidence concerns the gene ETS1 and neurodegenerative disease.